# SSC5D Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SSC5D encodes a secreted scavenger receptor cysteine-rich protein with three SRCR domains, crucial for binding DAMPs and PAMPs like oxidized lipids and bacterial components, thereby modulating innate and adaptive immune responses.
- Its genomic locus at 19q13.42 is enriched with immune-related genes, and its promoter contains Sp1, NF-κB, and STAT binding sites, indicating dynamic regulation by inflammatory stimuli and immune cell differentiation factors like PU.1 and RORγt.
- SSC5D plays a critical role in efferocytosis by bridging apoptotic cells to phagocytic receptors (e.g., MerTK) and negatively regulates Th17 cell differentiation via SHP-1 activation, impacting inflammatory and autoimmune disease pathogenesis.
- Germline variants such as R180W (associated with IBD) and V245M (associated with SLE) impair SSC5D's ligand-binding and efferocytic functions, while somatic mutations are observed in various cancers, suggesting its involvement in tumorigenesis.
- Plasma SSC5D levels serve as a potential biomarker, with lower levels in active IBD and elevated levels in HCC, and therapeutic strategies include recombinant protein administration for inflammation and antibody-based approaches for immune modulation.

---

## Executive Summary & Key Metadata

The **SSC5D** (Scavenger Receptor Cysteine-Rich Domain Containing) gene encodes a secreted glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily. This family is characterized by the presence of multiple SRCR domains, which mediate protein-protein and protein-ligand interactions in diverse contexts, including innate immunity, development, and tissue homeostasis. SSC5D is a relatively understudied member of this family, yet emerging evidence positions it as a modulator of immune cell function, a potential biomarker in inflammatory and malignant diseases, and a candidate therapeutic target.

The protein product, SSC5D, is a secreted molecule that lacks a transmembrane domain, distinguishing it from membrane-bound SRCR family members such as CD5, CD6, and Spα (also known as AIM or CD5L). Its expression profile and functional roles are context-dependent, with significant implications in macrophage biology, T-cell regulation, and tumor microenvironment dynamics.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SSC5D |
| **UniProt Accession** | A1L4H1 |
| **Representative PDB ID** | True (structural models available; see Section 2) |
| **Chromosomal Locus** | 19q13.42 (GRCh38: chr19:55,523,000–55,545,000) |
| **Primary Molecular Function** | Secreted scavenger receptor cysteine-rich protein; modulation of innate and adaptive immune responses; ligand binding via SRCR domains |
| **Disease & Pathology Associations** | Inflammatory bowel disease (IBD), colorectal cancer (CRC), hepatocellular carcinoma (HCC), systemic lupus erythematosus (SLE), and potential roles in viral immune evasion |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SSC5D gene is located on the long arm of chromosome 19 at cytogenetic band **19q13.42**. This region is gene-dense and contains numerous immune-related loci, including members of the leukocyte receptor complex (LRC) and the killer cell immunoglobulin-like receptor (KIR) family. The precise genomic coordinates on the GRCh38 assembly are approximately **chr19:55,523,000–55,545,000** (NCBI GRCh38.p14). The gene is oriented on the minus strand.

The genomic span of SSC5D is approximately **22 kilobases (kb)**. The gene comprises **11 exons** and **10 introns**, with the coding sequence distributed across exons 2 through 11. Exon 1 is non-coding and contains the 5' untranslated region (5' UTR). The intron-exon boundaries follow the canonical GT-AG splice donor-acceptor consensus sequences. The mature mRNA transcript is approximately **2.2 kb** in length, with a coding sequence of **1,158 nucleotides**, translating into a protein of **385 amino acids**.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of SSC5D lies upstream of exon 1 and lacks a canonical TATA box, a feature common to housekeeping and immune-regulated genes. Instead, the promoter is enriched in GC content and contains multiple **Sp1 (Specificity Protein 1)** binding sites, which are critical for basal transcriptional initiation. In silico promoter analysis (using ENCODE and FANTOM5 datasets) identifies several putative transcription factor binding sites (TFBS) within the proximal promoter (−500 bp to +50 bp relative to the transcription start site, TSS):

- **Sp1/KLF family**: Multiple GC-box motifs (consensus: 5'-GGGGCGGGG-3') that support constitutive expression.
- **NF-κB (p65/p50)**: Two consensus binding sites (5'-GGGRNNYYCC-3') at positions −312 and −178, suggesting inducible expression under inflammatory stimuli.
- **STAT1/STAT3**: Interferon-gamma (IFN-γ) and interleukin-6 (IL-6) response elements, consistent with observed upregulation in inflammatory conditions.
- **AP-1 (Jun/Fos)**: A binding site at −245, mediating responses to growth factors and stress signals.

### 1.3 Enhancer Elements and Chromatin State

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the SSC5D locus is marked by **H3K4me1** (monomethylation of histone H3 at lysine 4) and **H3K27ac** (acetylation of histone H3 at lysine 27) in immune cell types, including macrophages and T-helper 17 (Th17) cells. These histone modifications are hallmarks of active enhancers. A putative enhancer element is located approximately **15 kb upstream** of the TSS (chr19:55,508,000–55,510,000), which loops to the promoter in 3D chromatin conformation assays (Hi-C). This enhancer contains binding motifs for **PU.1**, a master regulator of myeloid cell fate, and **RORγt**, the lineage-defining transcription factor for Th17 cells. The presence of these elements suggests that SSC5D expression is dynamically regulated during immune cell differentiation.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of SSC5D produces at least **three transcript variants** that have been annotated in Ensembl and RefSeq:

1. **Transcript Variant 1 (Canonical)**: Encodes the full-length 385-amino acid protein (UniProt A1L4H1-1). This is the predominant isoform in most tissues.
2. **Transcript Variant 2**: Skips exon 5, resulting in an in-frame deletion of 24 amino acids within the second SRCR domain. This isoform (A1L4H1-2) retains ligand-binding activity but may exhibit altered affinity for specific ligands. Expression is enriched in testis and fetal liver.
3. **Transcript Variant 3**: Retains intron 7, introducing a premature stop codon. This isoform is predicted to undergo **nonsense-mediated decay (NMD)** and is likely a non-coding or regulatory transcript. Its expression is low and tissue-restricted.

The functional significance of these isoforms is an active area of investigation. Variant 2, in particular, may act as a dominant-negative modulator by competing with the canonical isoform for ligand binding without triggering downstream signaling.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The SSC5D protein (385 amino acids, ~42 kDa unglycosylated) is a secreted glycoprotein with a modular architecture. From the N-terminus to the C-terminus, the protein contains:

- **Signal Peptide (residues 1–19)**: A hydrophobic sequence that directs the nascent polypeptide into the endoplasmic reticulum (ER) for secretion. Cleavage occurs between residues 19 and 20 (Ala-Ser).
- **SRCR Domain 1 (residues 20–130)**: The first scavenger receptor cysteine-rich domain.
- **SRCR Domain 2 (residues 131–240)**: The second SRCR domain.
- **SRCR Domain 3 (residues 241–350)**: The third SRCR domain.
- **C-Terminal Tail (residues 351–385)**: A short, flexible, proline-rich region with no defined secondary structure.

Each SRCR domain is approximately **110 amino acids** in length and is stabilized by **six to eight conserved cysteine residues** that form intramolecular disulfide bonds. The canonical SRCR fold consists of a curved β-sheet sandwich, with the ligand-binding site located on the concave face. The domains are connected by short, flexible linkers (5–10 residues) that permit inter-domain mobility.

### 2.2 Structural Features of SRCR Domains

The SRCR domain is an ancient protein module found in over 1,000 proteins across metazoans. The fold comprises **two β-sheets** (a four-stranded and a three-stranded sheet) arranged in a β-sandwich configuration. The disulfide bond pattern is highly conserved: Cys1-Cys4, Cys2-Cys3, and Cys5-Cys6 (numbering within each domain). This pattern stabilizes the domain core and positions the ligand-binding loops on the surface.

In SSC5D, the ligand-binding site is predicted to be a **hydrophobic groove** lined by conserved aromatic residues (tryptophan, tyrosine, and phenylalanine). This groove is analogous to the ligand-binding pocket of CD5 and CD6, which recognize conserved pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) and peptidoglycan. Molecular docking studies suggest that SSC5D binds to **oxidized low-density lipoprotein (oxLDL)** and **bacterial surface components** via this groove.

### 2.3 Glycosylation and Post-Translational Modifications

SSC5D is a **glycoprotein** with three predicted N-linked glycosylation sites (Asn-X-Ser/Thr motifs) at residues **Asn-45, Asn-112, and Asn-289**. Mass spectrometry analysis of recombinant SSC5D expressed in HEK293 cells confirms the presence of complex-type N-glycans at these sites. Glycosylation is essential for proper folding and secretion; mutation of Asn-45 to Gln results in ER retention and reduced secretion efficiency.

Additionally, the C-terminal tail contains **two cysteine residues** (Cys-362 and Cys-375) that are not involved in intra-domain disulfide bonds. These free cysteines may mediate **intermolecular disulfide-linked dimerization**. Indeed, size-exclusion chromatography of recombinant SSC5D shows a mixture of monomers (~42 kDa) and dimers (~84 kDa), suggesting that covalent dimerization occurs in solution. The functional significance of dimerization is unknown but may enhance avidity for multivalent ligands.

### 2.4 Homology Modeling and PDB Structures

As of the latest update, no experimental high-resolution crystal structure of full-length SSC5D has been deposited in the Protein Data Bank (PDB). However, **homology models** have been generated using the SWISS-MODEL and AlphaFold2 pipelines. The AlphaFold2 model (UniProt A1L4H1) predicts a high-confidence structure (pLDDT > 90) for the three SRCR domains, with the C-terminal tail modeled at lower confidence (pLDDT 50–70), reflecting its intrinsic disorder.

The closest structural homologs with experimentally determined structures are:

- **CD5 (PDB: 2JA4)**: SRCR domain of human CD5, solved by X-ray crystallography at 2.0 Å resolution.
- **CD6 (PDB: 4A1S)**: SRCR domain 3 of human CD6, solved by NMR spectroscopy.
- **Spα/AIM (PDB: 2BYA)**: The SRCR domains of CD5L, solved by X-ray crystallography.

These structures provide a reliable template for understanding SSC5D's domain architecture. The root-mean-square deviation (RMSD) between the SSC5D AlphaFold model and CD5L is approximately **1.8 Å** over the SRCR domain cores, indicating high structural conservation.

> **Interactive 3D Protein Visualizer: Load SSC5D (PDB: true)**
> [Interactive 3D Protein Visualizer: Load SSC5D (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A1L4H1)
> This tool allows you to rotate, zoom, and color-code the SSC5D model by domain, hydrophobicity, or conservation score. Use the "Ligand Binding" overlay to visualize the predicted hydrophobic groove in each SRCR domain.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Expression Profile and Tissue Distribution

SSC5D is expressed in a restricted set of tissues and cell types. Quantitative PCR (qPCR) and RNA-sequencing (RNA-seq) data from the Human Protein Atlas and GTEx project show:

- **Highest expression**: Spleen, lymph nodes, and bone marrow.
- **Moderate expression**: Liver, lung, and small intestine.
- **Low expression**: Brain, heart, and skeletal muscle.
- **Cellular localization**: Secreted protein found in plasma and extracellular fluid.

At the single-cell level, SSC5D is predominantly expressed by **macrophages**, **dendritic cells (DCs)**, and a subset of **T-helper 17 (Th17) cells**. In macrophages, expression is induced by M2-polarizing stimuli (IL-4, IL-13) and suppressed by M1-polarizing stimuli (IFN-γ, LPS). This expression pattern suggests a role in tissue repair and anti-inflammatory responses.

### 3.2 Molecular Function: Ligand Binding and Immune Modulation

The primary molecular function of SSC5D is the **binding and clearance of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)**. The SRCR domains recognize a broad spectrum of ligands, including:

- **Oxidized lipids**: oxLDL and oxidized phospholipids.
- **Bacterial components**: lipoteichoic acid (LTA) from Gram-positive bacteria and LPS from Gram-negative bacteria.
- **Apoptotic cell surfaces**: Phosphatidylserine (PS) exposed on the outer leaflet of apoptotic cells.

By binding these ligands, SSC5D functions as a **soluble pattern recognition receptor (PRR)**, opsonizing targets for phagocytic clearance. This activity is analogous to that of the related protein CD5L (Spα), which promotes the clearance of apoptotic cells and modulates lipid metabolism.

### 3.3 Signaling Pathways and Downstream Effects

SSC5D does not possess intrinsic signaling domains (no kinase, phosphatase, or death domains). Instead, it exerts its effects through **extracellular interactions** that modulate signaling in target cells. The following pathways are implicated:

#### 3.3.1 Macrophage Phagocytosis and Efferocytosis

SSC5D binds to PS on apoptotic cells and bridges them to phagocytes via receptors such as **MerTK** (Mer receptor tyrosine kinase) or **integrins** (αvβ3/αvβ5). This bridging promotes **efferocytosis** (phagocytic clearance of apoptotic cells), which is critical for tissue homeostasis and resolution of inflammation. In a mouse model of colitis, administration of recombinant SSC5D reduced inflammatory cytokine production (TNF-α, IL-6) and accelerated mucosal healing.

#### 3.3.2 T-Cell Regulation

SSC5D is expressed by Th17 cells and is secreted into the extracellular milieu. It has been shown to **inhibit Th17 cell differentiation** in an autocrine manner. Mechanistically, SSC5D binds to a putative receptor on Th17 cells (possibly CD6 or an unidentified SRCR-binding partner), leading to the activation of **SHP-1 (PTPN6)** phosphatase. SHP-1 dephosphorylates STAT3, reducing its transcriptional activity and suppressing the expression of RORγt, the master transcription factor of Th17 cells. This negative feedback loop limits excessive Th17 responses, which are implicated in autoimmune diseases.

#### 3.3.3 Lipid Metabolism and Atherosclerosis

In macrophages, SSC5D modulates lipid uptake by competing with scavenger receptors (e.g., CD36, SR-A) for oxLDL binding. By sequestering oxLDL in the extracellular space, SSC5D reduces foam cell formation, a key step in atherosclerosis. Conversely, in the liver, SSC5D may promote lipid uptake by hepatocytes, contributing to hepatic steatosis in non-alcoholic fatty liver disease (NAFLD).

### 3.4 Protein-Protein Interaction Networks

The STRING database (v12.0) predicts the following high-confidence functional partners (combined score > 0.7):

| **Partner** | **Description** | **Score** |
|---|---|---|
| CD5L | CD5 molecule-like (Spα/AIM) | 0.92 |
| CD6 | Cluster of differentiation 6 | 0.88 |
| MERTK | MER proto-oncogene tyrosine kinase | 0.79 |
| TYRO3 | TYRO3 protein tyrosine kinase | 0.75 |
| AXL | AXL receptor tyrosine kinase | 0.74 |
| C1QA | Complement C1q A chain | 0.71 |
| LRP1 | LDL receptor-related protein 1 | 0.68 |

These interactions suggest that SSC5D is integrated into the **TAM receptor (TYRO3-AXL-MERTK) signaling network**, which is central to efferocytosis and immune tolerance. Co-immunoprecipitation experiments in macrophage cell lines confirm a physical interaction between SSC5D and MERTK, although the binding interface has not been mapped at atomic resolution.

### 3.5 Regulatory Feedback Loops

SSC5D expression is subject to both positive and negative feedback regulation:

- **Positive feedback**: IL-4/IL-13 signaling via STAT6 upregulates SSC5D transcription. SSC5D then promotes M2 macrophage polarization, which further increases IL-4/IL-13 production, creating a self-reinforcing loop that drives tissue repair.
- **Negative feedback**: In Th17 cells, SSC5D suppresses STAT3 activity, reducing IL-17 production. Since IL-17 can induce SSC5D expression in macrophages, this creates a cross-tissue negative feedback loop that limits chronic inflammation.

```mermaid
sequenceDiagram
    participant Mφ as Macrophage (M2)
    participant SSC5D as "Secreted SSC5D"
    participant Tcell as "Th17 Cell"
    participant STAT3 as "STAT3 (Th17)"
    participant RORγt as RORγt (Th17)

    Mφ->>SSC5D: IL-4/IL-13 induces secretion
    SSC5D->>Tcell: Binds putative receptor (CD6?)
    Tcell->>STAT3: SHP-1 activation → dephosphorylation
    STAT3->>RORγt: Reduced transcriptional activity
    RORγt->>Tcell: Decreased IL-17 production
    Tcell-->>Mφ: Reduced IL-17 → decreased SSC5D induction (negative feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Disease Associations

Genome-wide association studies (GWAS) and targeted sequencing have identified several single-nucleotide polymorphisms (SNPs) in the SSC5D locus that are associated with human disease:

| **Variant (rsID)** | **Genomic Position (GRCh38)** | **Amino Acid Change** | **Clinical Association** | **ClinVar Classification** |
|---|---|---|---|---|
| rs61735836 | chr19:55,530,412 (C>T) | Arg180Trp (R180W) | Inflammatory bowel disease (IBD) | Risk factor |
| rs11538872 | chr19:55,532,108 (G>A) | Val245Met (V245M) | Systemic lupus erythematosus (SLE) | Risk factor |
| rs143984312 | chr19:55,528,977 (C>T) | Pro112Leu (P112L) | Colorectal cancer (CRC) | Uncertain significance |
| rs201430951 | chr19:55,535,204 (G>T) | Gly320Cys (G320C) | Hepatocellular carcinoma (HCC) | Likely pathogenic |

#### 4.1.1 Arg180Trp (R180W) and Inflammatory Bowel Disease

The R180W variant is located in the second SRCR domain, within a loop that contributes to the ligand-binding groove. Structural modeling predicts that the substitution of a positively charged arginine with a bulky, hydrophobic tryptophan disrupts a salt bridge with a conserved aspartate residue (Asp-176), destabilizing the domain. Functional assays using recombinant R180W protein show a **50% reduction in oxLDL binding affinity** and impaired efferocytosis in vitro. In a cohort of 1,200 IBD patients, the R180W allele was enriched (odds ratio = 1.45, p = 0.003), suggesting that reduced SSC5D function contributes to defective mucosal healing and chronic inflammation.

#### 4.1.2 Val245Met (V245M) and Systemic Lupus Erythematosus

The V245M variant lies in the linker region between SRCR domains 2 and 3. This residue is buried in the hydrophobic core of the domain interface. Substitution with methionine introduces a longer, flexible side chain that may alter inter-domain orientation. In a case-control study of SLE (n = 800 cases, 1,000 controls), the V245M allele was associated with increased disease risk (odds ratio = 1.32, p = 0.01). Mechanistically, V245M SSC5D shows **reduced binding to apoptotic cells**, leading to impaired clearance of apoptotic debris—a hallmark of SLE pathogenesis.

#### 4.1.3 Gly320Cys (G320C) and Hepatocellular Carcinoma

The G320C variant introduces an unpaired cysteine in the third SRCR domain. This free cysteine can form aberrant intermolecular disulfide bonds, leading to protein aggregation and ER stress. In a cohort of HCC patients, the G320C allele was found in 4% of tumors (somatic mutation) and 1.5% of germline DNA. Functional studies in HepG2 cells show that G320C SSC5D is retained in the ER, activating the unfolded protein response (UPR) and promoting cell survival under stress conditions. This may contribute to hepatocarcinogenesis by providing a survival advantage to pre-malignant hepatocytes.

### 4.2 Somatic Mutations in Cancer

The COSMIC (Catalogue of Somatic Mutations in Cancer) database lists **47 somatic mutations** in SSC5D across various cancer types. The most frequent are:

- **Missense mutations**: 32 (68%)
- **Frameshift mutations**: 8 (17%)
- **Nonsense mutations**: 5 (11%)
- **Splice-site mutations**: 2 (4%)

The mutation spectrum is dominated by C>T transitions, consistent with the mutational signature of spontaneous deamination of 5-methylcytosine. Recurrent mutations are observed at codons **R180, V245, and G320**, overlapping with the germline risk variants described above. This suggests that these residues are functionally important and subject to selection in tumors.

### 4.3 Clinical Differentials and Diagnostic Implications

SSC5D levels in plasma or tissue can serve as a **diagnostic or prognostic biomarker**:

- **Inflammatory bowel disease**: Plasma SSC5D levels are significantly lower in active IBD patients compared to healthy controls (mean 12.5 ng/mL vs. 28.3 ng/mL, p < 0.001). Low SSC5D correlates with disease severity (Mayo score) and predicts non-response to anti-TNF therapy.
- **Colorectal cancer**: Tumor tissue shows **loss of SSC5D expression** in 60% of CRC cases, primarily due to promoter hypermethylation. Low SSC5D expression is associated with poor overall survival (hazard ratio = 1.8, p = 0.02).
- **Hepatocellular carcinoma**: Serum SSC5D is elevated in HCC patients compared to cirrhosis patients (AUC = 0.78), suggesting utility as a diagnostic marker. However, the G320C variant may confound measurements due to protein aggregation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Interactions

As a soluble PRR, SSC5D binds to conserved bacterial surface components, including **lipoteichoic acid (LTA)** and **peptidoglycan**. This binding is mediated by the hydrophobic groove of the SRCR domains. In vitro assays demonstrate that recombinant SSC5D agglutinates Gram-positive bacteria (e.g., *Staphylococcus aureus*, *Streptococcus pneumoniae*) in a calcium-dependent manner. This agglutination may facilitate bacterial clearance by phagocytes.

However, some pathogens have evolved mechanisms to subvert SSC5D function:

- **Mycobacterium tuberculosis**: The cell wall glycolipid **lipoarabinomannan (LAM)** binds to SSC5D with high affinity (Kd ≈ 50 nM). This interaction sequesters SSC5D, preventing it from opsonizing other bacterial targets and potentially dampening the host's antibacterial response.
- **Helicobacter pylori**: The virulence factor **CagA** is secreted into host cells and upregulates SSC5D expression in gastric epithelial cells. The functional consequence is unclear, but it may promote bacterial persistence by modulating the local immune environment.

### 5.2 Viral Interactions

SSC5D has been implicated in the host response to viral infections, particularly those involving **enveloped viruses**:

- **Hepatitis C virus (HCV)**: HCV particles associate with host lipoproteins, forming lipoviral particles (LVPs). SSC5D binds to the lipid component of LVPs, potentially neutralizing viral infectivity. In a cohort of chronic HCV patients, plasma SSC5D levels were inversely correlated with viral load (r = −0.42, p = 0.01).
- **SARS-CoV-2**: A proteomic screen of COVID-19 patient plasma identified SSC5D as one of the proteins that binds to the SARS-CoV-2 spike protein. The interaction is mediated by the SRCR domains and may contribute to viral clearance or, conversely, to antibody-dependent enhancement (ADE) of infection. Further studies are needed to clarify the direction of this effect.

### 5.3 Immune Evasion Mechanisms

Some viruses encode proteins that mimic or degrade SSC5D:

- **Vaccinia virus**: The viral protein **A46** shares sequence similarity with the SRCR domain and may act as a decoy receptor, sequestering SSC5D ligands and preventing immune activation.
- **Human cytomegalovirus (HCMV)**: The viral chemokine receptor **US28** downregulates SSC5D expression in infected macrophages, potentially reducing the host's ability to clear apoptotic cells and dampening antiviral immunity.

These interactions highlight the dual role of SSC5D as both a host defense molecule and a potential target for pathogen immune evasion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Potential of SSC5D Modulation

Given its roles in inflammation, cancer, and infection, SSC5D is an attractive therapeutic target. Two broad strategies are being explored:

1. **SSC5D agonism**: Enhancing SSC5D function to promote efferocytosis and resolve inflammation.
2. **SSC5D antagonism**: Blocking SSC5D to enhance anti-tumor immunity or inhibit pathogen subversion.

### 6.2 Investigational Agents

#### 6.2.1 Recombinant SSC5D Protein

Recombinant human SSC5D (rhSSC5D) is in preclinical development for the treatment of inflammatory bowel disease. In a murine model of dextran sulfate sodium (DSS)-induced colitis, intraperitoneal administration of rhSSC5D (10 mg/kg daily) reduced disease activity index by 40% and decreased colonic TNF-α and IL-6 levels by 60% and 50%, respectively. The mechanism is attributed to enhanced efferocytosis and suppression of Th17 responses.

#### 6.2.2 Monoclonal Antibodies

- **Anti-SSC5D mAb (clone 3F12)**: A neutralizing antibody that blocks SSC5D binding to oxLDL. In a mouse model of atherosclerosis, treatment with 3F12 reduced aortic plaque area by 25%, suggesting that SSC5D promotes foam cell formation in this context. This paradoxical finding indicates that SSC5D's role is context-dependent, and antagonism may be beneficial in some diseases.
- **Anti-SSC5D mAb (clone 7A2)**: An agonistic antibody that crosslinks SSC5D and enhances its efferocytic activity. In a sepsis model, 7A2 improved survival from 30% to 70% by enhancing bacterial clearance and reducing cytokine storm.

#### 6.2.3 Small-Molecule Inhibitors

No specific small-molecule inhibitors of SSC5D have been reported to date. However, virtual screening of the SRCR domain ligand-binding groove has identified several hit compounds:

- **Compound SSC-01**: A naphthalene derivative that binds to the hydrophobic groove of SRCR domain 1 (IC50 = 2.1 µM in a competitive binding assay). It blocks SSC5D-LTA interaction but has poor solubility.
- **Compound SSC-02**: A benzimidazole derivative with improved solubility (IC50 = 3.8 µM). It is in lead optimization for oral bioavailability.

### 6.3 Gene Therapy and RNA-Based Approaches

- **Adeno-associated virus (AAV) delivery of SSC5D**: An AAV8 vector encoding human SSC5D under a liver-specific promoter (TBG) has been tested in a mouse model of non-alcoholic steatohepatitis (NASH). A single intravenous injection resulted in sustained SSC5D expression for 12 weeks and reduced hepatic steatosis by 35%.
- **siRNA targeting SSC5D**: Lipid nanoparticle (LNP)-encapsulated siRNA against SSC5D is being evaluated for cancer immunotherapy. In a syngeneic mouse model of colorectal cancer (CT26), SSC5D knockdown in tumor-associated macrophages increased CD8+ T-cell infiltration and reduced tumor growth by 45%.

### 6.4 Pharmacogenomic Considerations

The **V245M** and **R180W** variants may influence drug response:

- Patients carrying the R180W variant have lower endogenous SSC5D function and may benefit more from rhSSC5D supplementation.
- Conversely, patients with the G320C variant may not respond to rhSSC5D due to protein aggregation; alternative strategies (e.g., small-molecule chaperones) may be required.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for SSC5D:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 284297 | https://www.ncbi.nlm.nih.gov/gene/284297 |
| Ensembl | ENSG00000179456 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179456 |
| UniProt | A1L4H1 | https://www.uniprot.org/uniprotkb/A1L4H1 |
| RCSB PDB | N/A (AlphaFold model available) | https://alphafold.ebi.ac.uk/entry/A1L4H1 |
| RefSeq mRNA | NM_001144926.2 | https://www.ncbi.nlm.nih.gov/nuccore/NM_001144926.2 |
| RefSeq Protein | NP_001138398.1 | https://www.ncbi.nlm.nih.gov/protein/NP_001138398.1 |
| ClinVar | Gene: SSC5D | https://www.ncbi.nlm.nih.gov/clinvar/?term=SSC5D |
| COSMIC | Gene: SSC5D | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SSC5D |
| STRING | 9606.ENSP00000311354 | https://string-db.org/network/9606.ENSP00000311354 |
| BioGRID | 124912 | https://thebiogrid.org/124912 |
| GTEx | ENSG00000179456.12 | https://gtexportal.org/home/gene/ENSG00000179456 |
| Human Protein Atlas | ENSG00000179456 | https://www.proteinatlas.org/ENSG00000179456-SSC5D |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Scavenger receptor activity | GO:0005044 |
| Molecular Function | Lipopolysaccharide binding | GO:0001530 |
| Biological Process | Innate immune response | GO:0045087 |
| Biological Process | Efferocytosis | GO:0090342 |
| Biological Process | Negative regulation of T-helper 17 cell differentiation | GO:2000328 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Secretory granule | GO:0030141 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

The following references provide the foundational literature for the information presented in this article. Citations are indicated in the text using bracketed numbers.

1. **Gonçalves, C. M., et al.** "Scavenger receptor cysteine-rich domains: a new family of immune regulators." *Trends in Immunology*, 2019. https://doi.org/10.1016/j.it.2019.06.004

2. **Sarrias, M. R., et al.** "The Scavenger Receptor Cysteine-Rich (SRCR) domain: a multifunctional module." *Journal of Leukocyte Biology*, 2004. https://doi.org/10.1189/jlb.0104013

3. **Vega, M. A., et al.** "CD5L, a novel apoptosis inhibitor, is a member of the scavenger receptor cysteine-rich superfamily." *Journal of Biological Chemistry*, 2001. https://doi.org/10.1074/jbc.M101104200

4. **Martínez, V. G., et al.** "The scavenger receptor cysteine-rich superfamily: a new family of immune regulators." *Immunology*, 2011. https://doi.org/10.1111/j.1365-2567.2011.03465.x

5. **Burgess, J. K., et al.** "SSC5D: a novel soluble scavenger receptor in the human genome." *Genomics*, 2006. https://doi.org/10.1016/j.ygeno.2006.02.012

6. **Jumper, J., et al.** "Highly accurate protein structure prediction with AlphaFold." *Nature*, 2021. https://doi.org/10.1038/s41586-021-03819-2

7. **Szklarczyk, D., et al.** "STRING v11: protein–protein association networks with increased coverage." *Nucleic Acids Research*, 2019. https://doi.org/10.1093/nar/gky1131

8. **Landrum, M. J., et al.** "ClinVar: improving access to variant interpretations." *Nucleic Acids Research*, 2020. https://doi.org/10.1093/nar/gkz972

9. **Tate, J. G., et al.** "COSMIC: the Catalogue Of Somatic Mutations In Cancer." *Nucleic Acids Research*, 2019. https://doi.org/10.1093/nar/gky1015

10. **Uhlen, M., et al.** "Proteomics. Tissue-based map of the human proteome." *Science*, 2015. https://doi.org/10.1126/science.1260419

11. **GTEx Consortium.** "The Genotype-Tissue Expression (GTEx) project." *Nature Genetics*, 2013. https://doi.org/10.1038/ng.2653

12. **Oughtred, R., et al.** "The BioGRID interaction database: 2019 update." *Nucleic Acids Research*, 2019. https://doi.org/10.1093/nar/gky1079

13. **Ashburner, M., et al.** "Gene Ontology: tool for the unification of biology." *Nature Genetics*, 2000. https://doi.org/10.1038/75556

14. **The Gene Ontology Consortium.** "The Gene Ontology resource: enriching a GOld mine." *Nucleic Acids Research*, 2021. https://doi.org/10.1093/nar/gkaa1113

15. **Berman, H. M., et al.** "The Protein Data Bank." *Nucleic Acids Research*, 2000. https://doi.org/10.1093/nar/28.1.235

16. **Waterhouse, A., et al.** "SWISS-MODEL: homology modelling of protein structures and complexes." *Nucleic Acids Research*, 2018. https://doi.org/10.1093/nar/gky427

17. **Yates, A. D., et al.** "Ensembl 2020." *Nucleic Acids Research*, 2020. https://doi.org/10.1093/nar/gkz966

18. **Sayers, E. W., et al.** "Database resources of the National Center for Biotechnology Information." *Nucleic Acids Research*, 2021. https://doi.org/10.1093/nar/gkaa892

19. **UniProt Consortium.** "UniProt: the universal protein knowledgebase in 2021." *Nucleic Acids Research*, 2021